SCHEMBL11377293

SCHEMBL11377293

Cn1ccc(-c2ccccc2N)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.53
KEAP1 Q14145 1/20 0.50
ALDH1A1 P00352 4/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
KDM4E B2RXH2 4/20 0.44
NPC1 O15118 2/20 0.44
GAA P10253 2/20 0.44
HSD17B10 Q99714 2/20 0.44
IDO1 P14902 1/20 0.43
ADRA1D P25100 1/20 0.41
ADRA1A P35348 1/20 0.41
ADRA1B P35368 1/20 0.41
TGFBR1 P36897 1/20 0.41
MAPT P10636 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
MEN1 O00255 1/20 0.41
RAB9A P51151 1/20 0.41
JAK2 O60674 2/20 0.39
JAK1 P23458 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15690505 0.79 KEAP1 (0.42) KMT2AKEAP1KDM4ENPC1ADRA1D
SCHEMBL30510135 0.78 KMT2A (0.56) KMT2AKEAP1ALDH1A1KDM4ENPC1
SCHEMBL25378345 0.78 KMT2A (0.56) KMT2AKEAP1ALDH1A1KDM4ENPC1
SCHEMBL1095492 0.78 KMT2A (0.55) KMT2AKEAP1ALDH1A1KDM4EHSD17B10
SCHEMBL16574032 0.78 KMT2A (0.55) KMT2AKEAP1ALDH1A1KDM4ENPC1
SCHEMBL29767299 0.78 KMT2A (0.55) KMT2AKEAP1ALDH1A1KDM4ENPC1
SCHEMBL1177044 0.76 KMT2A (0.53) KMT2AKEAP1KDM4EADRA1DADRA1A
SCHEMBL31128114 0.76 KMT2A (0.53) KMT2AKEAP1L3MBTL1NPC1IDO1
SCHEMBL2277762 0.76 KMT2A (0.53) KMT2AKEAP1L3MBTL1NPC1IDO1
SCHEMBL9383732 0.76 KMT2A (0.53) KMT2AKEAP1ALDH1A1NPC1IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4306518-A1 NOVEL PYRIMIDINE DERIVATIVE SHOWING INHIBITION EFFECT ON GROWTH OF CANCER CELLS Oncobix Co., Ltd. (KR) 2024-01-17 EP disclosed
WO-2022191664-A1 NOVEL PYRIMIDINE DERIVATIVE SHOWING INHIBITION EFFECT ON GROWTH OF CANCER CELLS 주식회사 온코빅스 2022-09-15 WO disclosed
US-20090203667-A1 PENTADIENAMIDE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-08-13 US disclosed
US-20090203667-A1 PENTADIENAMIDE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-08-13 US disclosed
EP-2050734-A1 PENTADIENAMIDE DERIVATIVE Kyowa Hakko Kirin Co., Ltd. (JP) 2009-04-22 EP disclosed
US-4260758-A MICROBIOCIDES BURROUGHS WELLCOME CO. (US) 1981-04-07 US disclosed
EP-0000541-A2 1H-Pyrimido-(4,5-c)-1,2-diazepines, methods for their preparation and compositions containing them; their use as intermediates for heterocyclic transformations. THE WELLCOME FOUNDATION LIMITED (GB) 1979-02-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203667-A1 PENTADIENAMIDE DERIVATIVES PRMT1, REN, NGLY1 KMT2A 772/4885KEAP1 3694/4885ALDH1A1 1143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.